Legalizing cannabis drives innovation, but not always to the benefit of patients or public health.

Legalizing cannabis sparks innovation in patents and products, yet many developments favor commercial interests over patient health. State laws expand access, but federal restrictions still limit research, leaving a gap between market growth and verified medical benefits.

While healthcare innovations are typically life-saving, not all advancements translate into tangible benefits for patients. This issue is particularly prominent in sectors where substances are either restricted or illicit, such as cannabis, stem cells, and cryptocurrencies. In these markets, researchers encounter significant barriers, including high costs, limited access to materials and data, and stringent regulatory requirements.

The Legal and Research Paradox in Cannabis

Cannabis illustrates a complex tension between regulatory restrictions and opportunities for research and innovation. Despite the federal government in the United States classifying cannabis as a substance with no recognized medical use, a growing number of states have legalized cannabis for either medical or recreational purposes. Adding another layer of complexity, the Department of Health and Human Services holds a cannabis-related patent granted in 2003, which covers potential medical uses to protect the brain from damage or degeneration. This patent has been exclusively licensed for commercial use.

Innovation in cannabis spans several domains:

• Clinical trials exploring cannabis as a treatment option, its effects on users, and its potential for abuse and addiction.
• Cannabis-related patents covering chemical formulations, production methods, or consumer products such as edibles, beverages, and vaporizers.

However, the question remains whether these innovations provide real benefits for patients or consumers.

Federal Restrictions and State Legalization

At the federal level, cannabis is classified as a Schedule I substance, meaning it is considered to have a high potential for abuse and no recognized medical use. This classification places stringent limits on research:

• Clinical trials require approval from both the FDA and the DEA, a process that can take over a year.
• Researchers are limited to using cannabis strains approved by the federal government and are generally prohibited from studying products available in state-regulated markets.

Efforts to ease these regulatory restrictions are ongoing. Meanwhile, state-level legalization has expanded:

• California passed the first medical cannabis law in 1996.
• By June 2025, 40 states are expected to permit medical cannabis use.
• As of January 2026, 24 states have legalized recreational cannabis, with regulations similar to those governing alcohol. Colorado and Washington led the first wave of legalization in 2012.

This patchwork of laws affects both research and innovation. States with more permissive policies reduce the cost of medical research and product development, even under federal restrictions. For instance, some researchers have participants purchase cannabis from legal dispensaries for the purposes of study.

Impact of State Legalization on Innovation

Researchers analyzed clinical trials and patent filings related to cannabis to assess the impact of state legalization on innovation. They categorized innovation in the following ways:

• Clinical trials: exploring potential treatments, effects, and issues of abuse and addiction.
• Patents: covering chemical compounds, medical applications, production techniques, and consumer products.

The analysis also included an evaluation of public health risks, focusing on patents involving THC, products with high misuse potential, and consumer-targeted items like potent formulations, edibles, and vaporizers.

Commercial Gains vs. Health Benefits

The findings indicate that the legalization of recreational cannabis is associated with an increase in patent activity, but the innovations are more commercially driven than focused on scientific or health-related advancements. Patents predominantly concentrate on cultivation equipment and consumer products. Clinical trials, on the other hand, have not shown significant growth, largely due to persistent barriers such as limited access to research-grade cannabis, funding difficulties, and the stigma surrounding federally controlled substances.

The Gap Between Products and Research

The rapid expansion of recreational cannabis products, including potent strains and diverse consumption methods, has far outpaced critical health research. This discrepancy can create public health risks, as exemplified by the 2019-2020 outbreak of lung injuries linked to unregulated vaping products containing cannabis. To align market innovation with public health goals, policies aimed at reducing obstacles to clinical research are essential.

Ongoing Policy Developments

Both the Biden and Trump administrations have discussed reclassifying cannabis as a Schedule III substance, acknowledging its medical uses and moderate potential for dependence. Such changes could facilitate more clinical research, improving the evidence base for cannabis products and addressing the current disconnect between market innovation and health outcomes. This research highlights the need to differentiate between innovations driven by commercial interests and those based on scientific evidence, while emphasizing the regulatory challenges and public health implications of cannabis legalization.

About the Research

The study was conducted by economists Lucy Xiaolu Wang and Nathan W. Chan from UMass Amherst. It was funded by the Institute for Humane Studies and the SERN Applied Microeconomics Workshop. The authors declared no conflicts of interest beyond their academic roles.

Sources:

• Legalizing cannabis drives innovation, but not always to the benefit of patients or public health
• Cannabis Research and Innovation: The Struggle to Balance Health and Market
• Federal Restrictions and Cannabis Legalization: A Study on the Impact of State-Level Laws
• Cannabis legalization spurs innovation, but not always in ways that benefit patients or public health